GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » Price-to-Free-Cash-Flow

LOVFF (Cannara Biotech) Price-to-Free-Cash-Flow : 24.26 (As of May. 18, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Price-to-Free-Cash-Flow?

As of today (2025-05-18), Cannara Biotech's share price is $0.9217. Cannara Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Feb. 2025 was $0.04. Hence, Cannara Biotech's Price-to-Free-Cash-Flow Ratio for today is 24.26.

The historical rank and industry rank for Cannara Biotech's Price-to-Free-Cash-Flow or its related term are showing as below:

LOVFF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.49   Med: 26.94   Max: 120
Current: 26.73

During the past 7 years, Cannara Biotech's highest Price-to-Free-Cash-Flow Ratio was 120.00. The lowest was 6.49. And the median was 26.94.

LOVFF's Price-to-Free-Cash-Flow is ranked worse than
54.69% of 512 companies
in the Drug Manufacturers industry
Industry Median: 23.52 vs LOVFF: 26.73

Cannara Biotech's Free Cash Flow per Share for the three months ended in Feb. 2025 was $-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.04.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Cannara Biotech was 512.50% per year.

During the past 7 years, Cannara Biotech's highest 3-Year average Free Cash Flow per Share Growth Rate was 44.80% per year. The lowest was -22.90% per year. And the median was 21.10% per year.


Cannara Biotech Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cannara Biotech's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Price-to-Free-Cash-Flow Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - 19.43

Cannara Biotech Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.50 32.73 19.43 7.12 28.16

Competitive Comparison of Cannara Biotech's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Price-to-Free-Cash-Flow falls into.


;
;

Cannara Biotech Price-to-Free-Cash-Flow Calculation

Cannara Biotech's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.9217/0.038
=24.26

Cannara Biotech's Share Price of today is $0.9217.
Cannara Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cannara Biotech  (OTCPK:LOVFF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cannara Biotech Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .